Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Capobianco

Showing results (11-20 of 76) with videos related to

Pageof 8
Sort By:
Neurology and Therapy|February 6, 2016
Peculiar Cytological Cerebrospinal Fluid Pattern in a Case of Encephalomyelitis During Anti-Tumor Necrosis Factor-α TherapyYana Motuzova, Alessia Di Sapio, Marco Capobianco, et al.
Plos One|May 17, 2016
Normative Values for Intertrial Variability of Motor Responses to Nerve Root and Transcranial Stimulation: A Condition for Follow-Up Studies in Individual SubjectsWalter Troni, Federica Melillo, Antonio Bertolotto, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|November 26, 2011
Natalizumab in aggressive multiple sclerosis after haematopoietic stem cell transplantationMarco Capobianco, Y Motuzova, J Frau, et al.
Journal of Neurology|December 15, 2010
One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patientsSimona Malucchi, Francesca Gilli, Marzia Caldano, et al.
Neurology and Therapy|December 10, 2015
Natalizumab Discontinuation and Treatment Strategies in Patients with Multiple Sclerosis (MS): A Retrospective Study from Two Italian MS CentersMarianna Lo Re, Marco Capobianco, Paolo Ragonese, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|July 10, 2008
Acute myeloid leukemia induced by mitoxantrone treatment for aggressive multiple sclerosisMarco Capobianco, Simona Malucchi, Stefano Ulisciani, et al.
Neurology and Therapy|December 5, 2016
High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational StudySimona Malucchi, Marco Capobianco, Marianna Lo Re, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 22, 2014
Interferon beta-related nephropathy and interstitial lung disease: a new association and a long-term warningMarco Capobianco, Giorgina Piccoli, Federica Neve Vigotti, et al.
Cephalalgia : an International Journal of Headache|April 25, 2015
The use of the 25 Sprotte needle markedly reduces post-dural puncture headache in routine neurological practiceAntonio Bertolotto, Maria Malentacchi, Marco Capobianco, et al.
Archives of Neurology|March 16, 2011
Loss of braking signals during inflammation: a factor affecting the development and disease course of multiple sclerosisFrancesca Gilli, Nicole Désirée Navone, Simona Perga, et al.
Pageof 8

Showing results (11-20 of 76) with videos related to

Sort By:
Pageof 8
Neurology and Therapy|February 6, 2016
Peculiar Cytological Cerebrospinal Fluid Pattern in a Case of Encephalomyelitis During Anti-Tumor Necrosis Factor-α TherapyYana Motuzova, Alessia Di Sapio, Marco Capobianco, et al.
Plos One|May 17, 2016
Normative Values for Intertrial Variability of Motor Responses to Nerve Root and Transcranial Stimulation: A Condition for Follow-Up Studies in Individual SubjectsWalter Troni, Federica Melillo, Antonio Bertolotto, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|November 26, 2011
Natalizumab in aggressive multiple sclerosis after haematopoietic stem cell transplantationMarco Capobianco, Y Motuzova, J Frau, et al.
Journal of Neurology|December 15, 2010
One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patientsSimona Malucchi, Francesca Gilli, Marzia Caldano, et al.
Neurology and Therapy|December 10, 2015
Natalizumab Discontinuation and Treatment Strategies in Patients with Multiple Sclerosis (MS): A Retrospective Study from Two Italian MS CentersMarianna Lo Re, Marco Capobianco, Paolo Ragonese, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|July 10, 2008
Acute myeloid leukemia induced by mitoxantrone treatment for aggressive multiple sclerosisMarco Capobianco, Simona Malucchi, Stefano Ulisciani, et al.
Neurology and Therapy|December 5, 2016
High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational StudySimona Malucchi, Marco Capobianco, Marianna Lo Re, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 22, 2014
Interferon beta-related nephropathy and interstitial lung disease: a new association and a long-term warningMarco Capobianco, Giorgina Piccoli, Federica Neve Vigotti, et al.
Cephalalgia : an International Journal of Headache|April 25, 2015
The use of the 25 Sprotte needle markedly reduces post-dural puncture headache in routine neurological practiceAntonio Bertolotto, Maria Malentacchi, Marco Capobianco, et al.
Archives of Neurology|March 16, 2011
Loss of braking signals during inflammation: a factor affecting the development and disease course of multiple sclerosisFrancesca Gilli, Nicole Désirée Navone, Simona Perga, et al.
Pageof 8